Venus Remedies Limited · NSE:VENUSREM

Venus Remedies — Investor Presentation (November 2014)

29 slides from Venus Remedies's investor presentation, Nov 13, 2014

  1. Slide 1: Doing what we know best - Research

    Doing what we know best - Research We are in the business of preserving and improving human life through Innovation We expect to create one billion US dollar Intellectual Property wealth by 2015

  2. Slide 2: Strong IP Wealth

    Strong IP Wealth  Portfolio of more than 75 injectables catering to Critical Care segments.  More than 100 Patents received out of 360 patents filed across the world.  15 research products under patent protection.  Have specialised focus towards growing epidemic of Antimicrobial  Resistance (AM

  3. Slide 3: Snapshot

    Snapshot Global Presence  In 60 Nations across 6 Continents 11 Overseas Marketing Offices Pan India Marketing Network  40+ Distributors network  1,500+ Stockist network  40,000+ Chemist network  1,00,000+ Speciality Doctors network 3 Manufacturing Units  One in Panchkula (India), one in Baddi

  4. Slide 4: Our Product Portfolio for Global Markets

    Our Product Portfolio for Global Markets R&D Products (Injectables) 5 Products; sold in 7 countries Oncology Liquid (Injectables) 10 Products in various dosage form; sold in 19 countries Oncology Lyophilized 12 Products ; sold in 13 countries Carbapenem (Injectables) 3 Products ; sold in 21 countrie

  5. Slide 5: We have 25 research based products and 15 are commercialized

    We have 25 research based products and out of these 15 are commercialized  Effective against MDR, ESBLs, NDM-1 prducing strains. Elores  Not only kills resistant pathogens but also prevents their spread  Antibiotic  Caters to HAP, Febrile Neutropenia Potentox  Antibiotic  Caters to MRSA, VRSA

  6. Slide 6: We have 25 research based products and 15 are commercialized

    We have 25 research based products and out of these 15 are commercialized  Intra-abdominal infection caused by various pathogens & Supime post operative infections.  Antibiotic  For Pseudomonas infections in Burns Zydotum  Antibiotic  For raised intracranial pressure,brain oedema, encephalitis

  7. Slide 7: We have 25 research based products and 15 are commercialized

    We have 25 research based products and out of these 15 are commercialised  Effective against LRTI, UTI, Skin & skin structure infections, Sulbactomax Otitis Media, Surgical prophylaxis.  Antibiotic  Wound healing therapy for treatment of Diabetic & Chronic Ampucare wound  Wound care  A topica

  8. Slide 8: Research products soon to be launched

    We have 25 research based products and out of these 4 are soon to be launched  Drug and Disease induced toxicity is reduced VRP 2011  Oncology  Novel Diagnostic Anti-cancer agent & early detection of tumors Tumatrek  Oncology  Drug-Protein-Polymer Conjugate for alleviating cancer DPPC  Oncolog

  9. Slide 9: Research products with international patents

    Research products with international patents • Launched in FY14. • FY 14 Revenue • FY 14 Revenue • FY 14 Revenue Revenue approx. approx. 3.96% of total approx. 2.22% of total approx. 1.43% of total sales. sales. sales. 0.93% of total sales. • Patent Expiry: 2025 • Patent Expiry: 2025 • Patent Expiry

  10. Slide 10: Research products with international patents

    Research products with international patents • FY14 Revenue approx. • FY 14 Revenue approx. • FY 14 Revenue approx. 1.40% of total sales. 1.30% of total sales. 3.04% of total sales. • Patent Expiry: 2025 • Patent Awaited • Patent Awaited • Patent Granted: India and Europe. • Patents in Process: In 2

  11. Slide 11: Research products with international patents

    Research products with international patents • FY 14 Revenue • Products included; • Launched in FY14. approx. 8.32% of total Pirotum, Zydotum, Revenue approx. 0.93% of sales. Ezenus, Taxedol and total sales. • Sulbactomax is Supime. • Patent Awaited ranked No. 1 by • FY 14 Revenue approx. Product sa

  12. Slide 12: Research is leading to profitable Growth

    Research is leading to profitable Growth Research & Development Key Research Areas  State-of-the-Art, VENUS MEDICINE RESEARCH CENTRE approved by Department of Scientific & Industrial Research (Govt.  Novel Drug Delivery System of India) and accredited with GLP Certification.  Formulation Developm

  13. Slide 13: Global Presence

    Global Presence North America South America Europe Africa Asia Asia Australia 9 Countries 4 Countries 12 Countries CIS, Middle East South East Asia 2 Countries 26 countries Dossiers: Dossiers : Dossiers: 14 Countries 11 Countries Dossier Dossiers: Total Filed : 58 Total Filed : 90 Total Filed :155 D

  14. Slide 14: Our Manufacturing and Research Facilities

    Our Manufacturing and Research Facilities INDIA GERMANY Unit I - Panchkula Venus Pharma Gmbh  Headquarters  100% Subsidiary  Manufacturing Site for Large Volume  Incorporated in 2006, the vision to Parenteral enhance the Global presence  Accredited with WHO – GMP ,Yemen – GMP,  Accredited with

  15. Slide 15: Unit I- Panchkula

    Unit I- Panchkula

  16. Slide 16: Unit II- Baddi

    Unit II- Baddi

  17. Slide 17: Unit III-Venusian's Chamber (An Upcoming Global Trade Centre)

    Unit III-Venusian's Chamber (An Upcoming Global Trade Centre)

  18. Slide 18: Unit IV- Venus Medicine Research Centre

    Unit IV- Venus Medicine Research Centre

  19. Slide 19: Unit V- Venus Pharma Gmbh, Germany

    Unit V- Venus Pharma Gmbh, Germany

  20. Slide 20: Financial Overview

    Financial Overview Rs. Cr. Rs. Cr. 550 526 140 133 500 461 130 118 450 12 0 40 5 106 400 110 357 100 350 89 312 90 300 80 74 264 70 64 250 60 200 50 150 40 30 100 20 50 10 0 0 FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 0 9 FY 10 FY 11 FY 12 FY 13 FY 14 Revenue EBIDTA Rs. Cr. Rs. Cr. 70 110 61 100 60 57

  21. Slide 21: Financial Overview: Forecast for next 3 years

    Financial Overview: Forecast for next 3 years Rs. Cr. Rs. Cr. 1100 330 1000 300 900 816 2 70 254 800 70 9 2 40 700 213 617 2 10 600 179 180 500 150 400 12 0 300 90 200 60 100 30 0 0 FY 15 FY 16 FY 17 FY 15 FY 16 FY 17 Revenue EBIDTA Rs. Cr. 180 160 139 140 120 113 100 92 80 60 40 20 0 FY 15 FY 16 FY

  22. Slide 22: Revenue Segmentation by Product and Geography - 2014

    Revenue Segmentation by Product and Geography - 2014 25% 34% Segment wise Small Volume Parenterals 11% Infusion Oncology Cephalosporin 30% and Penem 9% 40% 19% Domestic Europe ROW 17% Strategic Alliances Institutional 15% Division wise

  23. Slide 23: Revenue Segmentation by Product and Geography – Forecast for 3 yrs

    Revenue Segmentation by Product and Geography – Forecast for 3 yrs Total Revenue Segmentation in Rs. Cr. Total Revenue Segmentation in Rs. Cr. 460 537 617 709 816 460 537 617 709 816 100 % 10 0% 9% 9% 8% 5% 20% 19% 6% 22% 90 % 7% 90 % 4% 9% 15% 80 % 80 % 9% 10% 12% 21% 70 % 70 % 21% 20% 60 % Regulat

  24. Slide 24: Recognition

    Recognition Ampucare Gold The BIZZ Medal 2010 Emerging India Award Business Excellence 'India Innovation 2007 Award 2011 Program - 2010' Presented by Received the award organized by Lockheed Dr. Manmohan Singh from US in 2011 Martin (USA), FICCI and Prime Minister of India DST (India) Patent Award Q

  25. Slide 25: Recognition

    Recognition 2011 Spotlight Award Trois: For Annual Report Gold Medal 2011 Won LACP's (League 'India Innovation of American Venus among the Top Communications 100 Best Companies to Programme - 2011' Professionals) Global work for- Great Place to organized by Lockheed Communication Competition Work 20

  26. Slide 26: Recognition

    Recognition Company of the Year 2011 Manufacturing Best SMB Award 2008 In the 4th Annual Pharmaceutical Leadership Leadership and Summit Award 2012 2011 UBM India Pharma Award for ELORES Venus among the Best Innovative 100 Award for Receives award in Companies to Work ELORES Excellence in Product fo

  27. Slide 27: Recognition

    Recognition Manufacturing Plants Ranking Accredited with GMP- European GMP – TGA Australia Among world's Top 500 GMP- Columbian (INVIMA) Largest Pharmaceutical GMP-Ukrainian Manufacturing Companies GMP- Zimbabwe GMP- Uganda Among World's 10 leading GMP- Syrian fixed dosages injectable GMP-Sudan Manu

  28. Slide 28: Management

    Management  Pawan Chaudhary  Chairman and Managing Director, Promoter  B.Com, FCA, LLB  Dr. Manu Chaudhary  Joint Managing Director  Msc., M.Phil (Genetics), PhD  Peeyush Jain  Deputy Managing Director  B.Tech, MBA  Ashutosh Jain  Executive Director  B. A., LLB

  29. Slide 29: Thank You !!!

    a» O, ® VENUS Enjoy Innovations Thank You !!!

Venus Remedies — Investor Presentation (November 2014) on 6ix